Evotec SE (NASDAQ:EVO) Stock Position Raised by DCF Advisers LLC

DCF Advisers LLC increased its holdings in Evotec SE (NASDAQ:EVO) by 5.9% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 229,871 shares of the company’s stock after acquiring an additional 12,816 shares during the period. DCF Advisers LLC’s holdings in Evotec were worth $956,000 at the end of the most recent reporting period.

Separately, Wellington Management Group LLP boosted its holdings in Evotec by 29.7% during the third quarter. Wellington Management Group LLP now owns 2,634,434 shares of the company’s stock valued at $9,616,000 after acquiring an additional 602,858 shares during the period. 5.81% of the stock is owned by hedge funds and other institutional investors.

Evotec Stock Performance

NASDAQ EVO opened at $3.52 on Friday. The company has a current ratio of 2.09, a quick ratio of 1.99 and a debt-to-equity ratio of 0.43. The firm has a 50-day simple moving average of $4.16 and a 200 day simple moving average of $4.09. Evotec SE has a twelve month low of $2.85 and a twelve month high of $7.98.

Evotec Profile

Evotec SE operates as drug discovery and development partner for the pharmaceutical and biotechnology industry worldwide. The company is developing pharmaceutical products in various therapeutic areas, such as autoimmune diseases, cancer, CNS diseases, diabetes, fibrosis, immunology, infectious diseases, kidney diseases, liver diseases, pain and inflammation, rare diseases, respiratory diseases, tuberculosis, and women’s health.